6505--770_Pharmaceuticals_VA CMOP National Office_36C77024Q0292 OGC Review
ID: 36C77024Q0292Type: Solicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNATIONAL CMOP OFFICE (36C770)LEAVENWORTH, KS, 66048, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/b2bc0df92cb44b818174280c7b385356/view
Timeline
    Description

    The Department of Veterans Affairs (VA) is seeking qualified vendors to supply Tamsulosin HCL 0.4mg capsules under solicitation number 36C77024Q0292 for delivery to multiple VA Consolidated Mail Outpatient Pharmacy (CMOP) facilities. The procurement involves a special requirement for the delivery of specific quantities of Tamsulosin HCL capsules, with an emphasis on compliance with the Drug Supply Chain Security Act (DSCSA) and the Buy American statute. This initiative is crucial for ensuring that veterans receive safe and compliant medications, thereby supporting their healthcare needs. Interested vendors must submit their quotes, including a signed SF1449 form, a detailed price schedule in Excel format, and proof of a State Wholesale Distributor License by July 9, 2024, with the anticipated award date set for July 12, 2024. For further inquiries, vendors can contact Michael W. McAlhaney at Michael.McAlhaney@va.gov or by phone at (913) 684-0134.

    Point(s) of Contact
    Michael W McAlhaneyContracting Specialist
    Michael.McAlhaney@va.gov
    Files
    Title
    Posted
    _rels/.rels
    [Content_Types].xml
    36C77024Q0292_1.docx
    The document outlines the solicitation and contractual requirements for pharmaceutical products to be supplied to the Department of Veterans Affairs (VA) under solicitation number 36C77024Q0292. It specifies the solicitation's purpose, which includes a focus on providing Tamsulosin HCL capsules for veterans' healthcare needs. Key requirements include submitting a signed SF1449 form, a detailed price schedule in Excel format, and proof of a State Wholesale Distributor License. The document emphasizes compliance with the Drug Supply Chain Security Act (DSCSA), requiring detailed transaction history, information, and statements for pharmaceuticals supplied. It highlights delivery logistics, including tracking requirements, coordination with VA facilities, and the need for barcoded labeling on all products. Additionally, the document enforces stringent standards for therapeutic equivalence and FDA compliance. Terms outline invoicing procedures, payment processes, and conditions under which contracts may be terminated. This solicitation is crucial for ensuring that the VA procures safe, compliant medications while promoting small business participation, particularly service-disabled veteran-owned firms. The comprehensive guidelines aim to streamline procurement and safeguard the welfare of veterans through effective supply chain management.
    36C77024Q0292.docx
    52.225-2 BUY AMERICAN CERTIFICATE.docx
    The document outlines the Buy American Certificate requirements as part of federal procurement processes, specifically aimed at soliciting offers for end products. It mandates that offerors certify each end product as domestic, aside from specified exceptions. The document requires offerors to identify any foreign end products and disclose their country of origin, as well as assess whether these products exceed 55% domestic content, unless categorically defined as commercially available off-the-shelf (COTS) items. A separate list must be provided for domestic products that include critical components. The evaluation of offers will be conducted under the established guidelines set forth in the Federal Acquisition Regulation (FAR), specifically part 25, which governs the Buy American Act and related provisions. This certificate is integral to ensuring compliance with U.S. production standards in federal acquisitions, promoting domestic manufacturing while regulating the inclusion of foreign goods.
    docProps/app.xml
    docProps/core.xml
    P02_NMR Individual Waiver Approval 36C77024Q0292_Redacted.pdf
    The document outlines the principles and practices employed by the Small Business Administration (SBA) regarding the provision of its programs and services. It emphasizes a commitment to nondiscrimination, ensuring that all SBA services are accessible to the public without bias. Although the content appears heavily garbled, the fundamental message indicates a structured approach to supporting diverse groups and promoting equitable access to federal resources. The SBA's focus aligns with its mission to enhance small business growth, especially through federal grants and Requests for Proposals (RFPs). This support is essential for state and local initiatives in fostering entrepreneurship and economic development. By actively removing barriers to participation, the SBA plays a pivotal role in fostering an inclusive business environment, ultimately contributing to community and economic resilience. Such efforts and policies are vital, particularly in the context of federal and state funding opportunities, ensuring fair participation for all stakeholders in government contract opportunities.
    S02_Solicitation_Attachment_Pricing SpreadSheet_RFQ_36C77024Q0292.xlsx
    The document outlines a Request for Quote (RFQ) from the Department of Veterans Affairs (VA) for Tamsulosin HCL 0.4mg capsules, packaged in quantities of 500. The RFQ, identified as 36C77024Q0292, is set to be issued on July 1, 2024, with quotes due by July 9, 2024. The award date is anticipated for July 12, 2024, and delivery timelines are still to be determined. Compliance with the Drug Supply Chain Security Act (DSCSA) is mandatory, requiring vendors to submit state wholesale distributor licensure with their quotes. Documentation related to compliance, like the Transaction History, Information, and Statement, must be submitted electronically via specific VA procurement emails. Required documents include a signed SF1449, a price schedule, and a completed Buy American Certificate. The distribution will involve multiple delivery points across different VA CMOP facilities. This RFQ demonstrates the VA's ongoing commitment to securing necessary medications through compliant and responsible procurement practices.
    word/_rels/document.xml.rels
    word/document.xml
    word/fontTable.xml
    word/footer1.xml
    word/numbering.xml
    word/settings.xml
    word/styles.xml
    word/theme/theme1.xml
    word/webSettings.xml
    Similar Opportunities
    6505--763-24-3-021-1011 -Lancaster CMOP CLOMIPHENE CITRATE -(VA-24-00076661)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified vendors to supply Clomiphene Citrate 50mg tablets for delivery to the Lancaster Consolidated Mail Outpatient Pharmacy (CMOP) facility in Texas. The procurement involves a requirement for 480 units of the specified pharmaceutical, with a focus on compliance with the Drug Supply Chain Security Act and other federal regulations. This opportunity is particularly significant as it supports the VA's commitment to ensuring a reliable supply of essential medications for veterans while promoting small business participation in federal contracting. Interested suppliers must submit their quotations, including a signed solicitation cover page, a completed price schedule, a valid State Wholesale Distributor License, and a Buy American Act certificate by September 17, 2024, at 3:00 PM Central Time. For further inquiries, vendors can contact Kelley Cunningham at Kelley.Cunningham@va.gov or call 913-684-0140.
    6505--770-24-4-801-0686 -National CMOP CLINDAMYCIN -(VA-24-00096153)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified vendors to provide Clindamycin PO4 1% Top Swab for delivery to multiple Compounding Medication Outpatient Pharmacies (CMOP) across the country. This procurement aims to secure approximately 3,584 units of the specified pharmaceutical product, ensuring compliance with federal regulations and the Drug Supply Chain Security Act (DSCSA). The goods are essential for the VA's healthcare services, supporting the treatment of various medical conditions. Interested vendors must submit their quotations by September 6, 2024, including a signed SF1449 cover page, a price schedule, proof of a valid State Wholesale Distributor License, and a Buy American Act Certificate. For further inquiries, vendors can contact Kelley Cunningham at kelley.cunningham@va.gov or call 913-684-0140.
    6505--Prasugrel HCL 5mg and 10mg 30 Count Bottles
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking proposals for the procurement of Prasugrel Hydrochloride (HCL) tablets in 5mg and 10mg 30-count bottles. The Request for Proposal (RFP) outlines specific requirements for offerors, including pricing for a base year and four optional one-year periods, compliance with federal regulations, and the provision of unique National Drug Code (NDC) numbers. This procurement is crucial for ensuring a reliable supply of essential medications to support veterans and related healthcare providers under the VA and Department of Defense's Pharmaceutical Prime Vendor Programs. Interested parties must submit their proposals by October 8, 2024, at 2:30 PM Central Standard Time, and can direct inquiries to Contract Specialist Matthew S. Poulin at Matthew.Poulin@va.gov.
    8145--Medication Return Envelopes (VA-24-00012799)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking proposals for the procurement of Medication Return Envelopes under solicitation number 36C77024Q0051. This initiative aims to supply multiple Veterans Affairs Medical Centers (VAMCs) and Consolidated Mail Outpatient Pharmacies (CMOP) with a system for the safe disposal of scheduled and non-controlled medications over a five-year period, from November 2024 to October 2029. The program is critical for enhancing medication safety, preventing accidental overdoses, and reducing environmental waste, with an estimated budget of $47 million. Interested vendors must submit their bids by October 14, 2024, at 5 PM Central Time, and are encouraged to monitor SAM.gov for further solicitation details, which will be posted on September 13, 2024. For inquiries, contact Contract Specialist Diana Olson at Diana.Olson@va.gov or 913-684-0153.
    6505--CGRP Calcitonin Gene-Related Peptides
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Calcitonin Gene-Related Peptides (CGRP) to support various healthcare programs, including those for Consolidated Mail Order Pharmacies and State Veterans Homes. The contract will require the successful offeror to provide a consistent supply of specified CGRP products, which are critical for treating patients with certain medical conditions, ensuring uninterrupted access to these essential medications. The solicitation is expected to be released on or about October 10, 2024, with a closing date of October 24, 2024, and interested parties should direct inquiries to Contracting Officer Chris Carthron at Christopher.Carthron@va.gov or by phone at (708) 786-4980. The contract will span one year with four additional one-year options, and all relevant documents will be available electronically at sam.gov.
    6505--Abiraterone Acetate Tablets
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting offers for the supply of Abiraterone Acetate tablets, a pharmaceutical product critical for various government healthcare facilities, including the VA and DoD. The procurement aims to establish a reliable source through competitive contracting, requiring offerors to provide pricing for a base year and four option years, along with an NDC number for their products. Abiraterone Acetate is essential for treating specific cancers, underscoring the importance of ensuring consistent availability of this medication to support patient care. Interested vendors should contact Contract Specialist Richard Mahario at Richard.Mahario@va.gov for further details, and must comply with specific packaging, labeling, and manufacturing standards as outlined in the solicitation document.
    6505--Bupropion Tablets
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is soliciting proposals for the procurement of Bupropion Hydrochloride tablets to support veterans and related entities through its Pharmaceutical Prime Vendor (PPV) Programs. Offerors are required to submit pricing that includes a 0.5% Cost Recovery Fee and provide unique National Drug Code (NDC) numbers for their products, while ensuring compliance with the Drug Supply Chain Security Act (DSCSA) and FDA regulations. This procurement is crucial for maintaining a reliable pharmaceutical supply for VA healthcare facilities, with a strong emphasis on participation from small and disadvantaged businesses. Interested parties should contact Contract Specialist Andrew J. Cazares at Andrew.Cazares@va.gov for further details regarding submission requirements and deadlines.
    MSPV Q4 FY24 SOLICITATION
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is issuing a Request for Quote (RFQ) for the Medical/Surgical Prime Vendor (MSPV) program, specifically to amend a prior solicitation aimed at establishing or modifying Blanket Purchase Agreements (BPAs) for the procurement of medical and surgical supplies. This initiative is critical for equipping approximately 1,243 healthcare facilities with essential supplies, ensuring compliance with the Federal Acquisition Regulation (FAR) and the Trade Agreements Act while focusing on cost-effectiveness and quality. Interested suppliers must submit proposals detailing pricing and hold appropriate distributor agreements, with BPAs potentially lasting up to 60 months without obligating the government to purchase. For further inquiries, contact Princess Mersha at princess.mersha@va.gov or Rashaun Thomas at Rashaun.Thomas@va.gov, with proposals due as specified in the solicitation amendment dated September 25, 2024.
    Q517--Staffing Service Tucson
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking proposals for staffing services at the Tucson Consolidated Mail Outpatient Pharmacy (CMOP), specifically targeting Service-Disabled Veteran-Owned Small Businesses (SDVOSBs). The contract requires the provision of pharmacists, pharmacy technicians, and shipper/packer personnel to support the processing of over 15 million prescriptions annually, with a minimum contract value of $4 million and a maximum of $250 million over five ordering periods from April 1, 2023, to March 31, 2028. This procurement is critical for maintaining efficient pharmaceutical operations and ensuring compliance with federal regulations, including HIPAA. Interested contractors must submit their proposals by the newly established deadline of July 23, 2024, and can direct inquiries to Contract Specialist Nicholas L. Schulte at nicholas.schulte1@va.gov or Christy Pendlay at christy.pendlaly@va.gov.
    Q517--Staffing Service MbM
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking proposals for staffing services under the Meds by Mail (MbM) program, specifically targeting Service-Disabled Veteran-Owned Small Businesses (SDVOSB). The procurement aims to provide licensed pharmacists and certified pharmacy technicians to support prescription processing across three facilities located in Dublin, GA; Cheyenne, WY; and Murfreesboro, TN. This initiative is crucial for enhancing healthcare services for veterans, ensuring efficient medication management and compliance with established protocols. Interested vendors must submit their proposals by the newly established deadline of August 6, 2024, and can direct inquiries to Contract Specialist Nicholas L. Schulte at nicholas.schulte1@va.gov or Christy Pendlay at christy.pendlaly@va.gov. The contract has a minimum guarantee of $2 million and a maximum potential value of $100 million over its five-year duration.